We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Comprehensive Influenza and Respiratory Virus Testing Service Launched

By LabMedica International staff writers
Posted on 01 Sep 2009
A new suite of tests identifies 2009 Influenza A H1N1, additional influenza subtypes, and other common respiratory viruses, such as rhinovirus, respiratory syncytial virus (RSV), and human metapneumovirus (HMPV). More...


The suite of four tests was launched by ViraCor-IBT Laboratories (Lee's Summit, MO, USA) as part of its influenza and respiratory virus testing service. They include the xTAG Respiratory Viral Panel (RVP), which detects 12 common respiratory viruses; a ViraCor-IBT-developed test specifically designed to detect 2009 Influenza A H1N1; a test to help physicians distinguish between the Influenza A H1 and Influenza A H3 subtypes; and a test that identifies antiviral-resistant mutations of the 2009 Influenza A H1N1.

The new testing service offers physicians and laboratories several ordering options, including reflex testing, which allows ViraCor-IBT to perform a second test without having to contact the ordering physician. It provides fast, accurate results within 24 hours and will help physicians pinpoint the cause of an infection, reduce unnecessary use of antivirals, and improve patient care.

"Correctly diagnosing a respiratory viral infection from a patient's symptoms alone is very difficult because most respiratory viruses cause very similar symptoms. The only way to be certain which pathogen is causing the infection is to run a laboratory test,” said Steve Kleiboeker, Ph.D., CSO for the combined ViraCor-IBT Laboratories. "With the emergence of antiviral-resistant viruses and new pathogens such as the pandemic Influenza A H1N1, testing for respiratory viruses has never been more important.”

All of ViraCor-IBT's respiratory virus testing options became available on September 1, 2009, except the 2009 Influenza A H1N1 antiviral resistance test, which is expected to be available later in the month.

ViraCor Laboratories and IBT Laboratories (Lenexa, KS, USA) merged in June 2009 to form a specialty diagnostics laboratory. The combined company specializes in cellular, immunology, and allergy testing services as well as molecular assays that detect and monitor microbial pathogens.

Related Links:
ViraCor-IBT Laboratories
IBT Laboratories



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.